Inhibitors of CXC chemokine receptor type 4: Putative therapeutic approaches in inflammatory diseases

Current Opinion in Hematology

Volumn 21, Issue 1, 2014, Pages 29-36

  Hummel, Stephanie ^a,b   Van Aken, Hugo ^a   Zarbock, Alexander ^a,b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Max Plank Institute Muenster   (Germany)

Author keywords

CXC chemokine receptor type 4 antagonist; CXCL12 CXC chemokine receptor type 4 axis; plerixafor (AMD3100)

Indexed keywords

3F BENOYL TN 14003; CALCIUM; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; COLLAGEN TYPE 1; G PROTEIN COUPLED RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; PLERIXAFOR; POLYPHEMUSIN; STROMAL CELL DERIVED FACTOR 1; T 140; TACHYPLESIN; TF 14016; TN 14003; ULOCUPLUMAB; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CALCIUM CELL LEVEL; CD4+ T LYMPHOCYTE; CELL HOMING; CHRONIC INFLAMMATION; COLITIS; DISEASE SEVERITY; ENTERITIS; FIBROSING ALVEOLITIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN DEFICIENCY; INFECTION; INFLAMMATORY DISEASE; LUNG FIBROSIS; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; MEMORY T LYMPHOCYTE; METASTASIS; MYELOMA; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STEM CELL MOBILIZATION; VERRUCA VULGARIS; WHIM SYNDROME;

CHEMOKINE CXCL12; DNA-BINDING PROTEINS; HUMANS; INFLAMMATION; LEUKOCYTES; NEUTROPHILS; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84890554352     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000002     Document Type: Review

References (100)

1. Eash KJ, Means JM, White DW, Link DC. CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. Blood 2009; 113:4711-4719.
2. Burdon PC, Martin C, Rankin SM. Migration across the sinusoidal endothelium regulates neutrophil mobilization in response to ELR CXC chemokines. Br J Haematol 2008; 142:100-108.
3. Inoue S, Osmond DG. Basement membrane of mouse bone marrowsinusoids shows distinctive structure and proteoglycan composition: A high resolution ultrastructural study. Anat Rec 2001; 264:294-304.
4. Petrides PE, Dittmann KH. How do normal and leukemic white blood cells egress from the bone marrow Morphological facts and biochemical riddles. Blut 1990; 61:3-13.
5. Christopher MJ, Link DC. Regulation of neutrophil homeostasis. Curr Opin Hematol 2007; 14:3-8.
6. Summers C, Rankin SM, Condliffe AM, et al. Neutrophil kinetics in health and disease. Trends Immunol 2010; 31:318-324.
7. Semerad CL, Liu F, Gregory AD, et al. G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity 2002; 17:413-423.
8. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7:678-689.
9. Butcher EC, Williams M, Youngman K, et al. Lymphocyte trafficking and regional immunity. Adv Immunol 1999; 72:209-253.
10. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 2000; 12:336-341.
11. Zlotnik A, Yoshie O. Chemokines: A new classification system and their role in immunity. Immunity 2000; 12:121-127.
12. Herter J, Zarbock A. Integrin regulation during leukocyte recruitment. J Immunol 2013; 190:4451-4457. In this review, different signaling pathways leading to the change of integrin adhesiveness in neutrophils, monocytes, and lymphocytes are described. Crucial steps of the leukocyte recruitment cascade, including rolling, adhesion, postadhesion strengthening, intravascular crawling, and transmigration, are highlighted.
13. Zarbock A, Ley K. Neutrophil adhesion and activation under flow. Microcirculation 2009; 16:31-42.
14. Yago T, Shao B, Miner JJ, et al. E-selectin engages PSGL-1 and CD44 through a common signaling pathway to induce integrin alphaLbeta2-mediated slow leukocyte rolling. Blood 2010; 116:485-494.
15. Balabanian K, Lagane B, Infantino S, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005; 280:35760-35766.
16. Mellado M, Rodriguez-Frade JM, Manes S, Martinez AC. Chemokine signaling and functional responses: The role of receptor dimerization and TK pathway activation. Annu Rev Immunol 2001; 19:397-421.
17. Murphy PM, Baggiolini M, Charo IF, et al. International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52:145-176.
18. Zhan W, Liang Z, Zhu A, et al. Discovery of small molecule CXCR4 antagonists. J Med Chem 2007; 50:5655-5664.
19. Lefrancois M, Lefebvre MR, Saint-Onge G, et al. Agonists for the chemokine receptor CXCR4. ACS Med Chem Lett 2011; 2:597-602.
20. Wu B, Chien EY, Mol CD, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010; 330:1066-1071.
21. Tashiro K, Tada H, Heilker R, et al. Signal sequence trap: A cloning strategy for secreted proteins and type I membrane proteins. Science 1993; 261:600-603.
22. Wald O, Pappo O, Safadi R, et al. Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol 2004; 34:1164-1174.
23. Ding Z, Jia SH, Marshall JC, et al. Up-regulation of functional CXCR4 expression on human lymphocytes in sepsis. Crit Care Med 2006; 34:3011-3017.
24. Lapidot T, Dar A, Kollet O. How do stem cells find their way home Blood 2005; 106:1901-1910.
25. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392:565-568.
26. Choi WT, Duggineni S, Xu Y, et al. Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4). J Med Chem 2012; 55:977-994. This study describes the pivotal role of CXCR4 and its antagonists in autoimmune diseases, including RA. The authors illustrate important aspects and perspectives in drug discovery research targeting CXCR4.
27. Xue G, Hemmings BA. PKB/Akt-dependent regulation of cell motility. J Natl Cancer Inst 2013; 105:393-404.
28. Servant G, Weiner OD, Herzmark P, et al. Polarization of chemoattractant receptor signaling during neutrophil chemotaxis. Science 2000; 287:1037-1040.
29. Martin C, Burdon PC, Bridger G, et al. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity 2003; 19:583-593.
30. Nagase H, Miyamasu M, Yamaguchi M, et al. Cytokine-mediated regulation of CXCR4 expression in human neutrophils. J Leukoc Biol 2002; 71:711-717.
31. Hsieh MM, Everhart JE, Byrd-Holt DD, et al. Prevalence of neutropenia in the U.S. population: Age, sex, smoking status, and ethnic differences. Ann Intern Med 2007; 146:486-492.
32. Ruggiero C, Metter EJ, Cherubini A, et al. White blood cell count and mortality in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol 2007; 49:1841-1850.
33. Peters LL, Cheever EM, Ellis HR, et al. Large-scale, high-throughput screening for coagulation and hematologic phenotypes in mice. Physiol Genomics 2002; 11:185-193.
34. Campbell FR. Ultrastructural studies of transmural migration of blood cells in the bone marrow of rats, mice and guinea pigs. Am J Anat 1972; 135:521-535.
35. Weiss L. Transmural cellular passage in vascular sinuses of rat bone marrow. Blood 1970; 36:189-208.
36. Petty JM, Lenox CC, Weiss DJ, et al. Crosstalk between CXCR4/stromal derived factor-1 and VLA-4/VCAM-1 pathways regulates neutrophil retention in the bone marrow. J Immunol 2009; 182:604-612.
37. Metcalf D. Hematopoietic cytokines. Blood 2008; 111:485-491.
38. Kim HK, De La Luz Sierra M, Williams CK, et al. G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood 2006; 108:812-820.
39. Levesque JP, Liu F, Simmons PJ, et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood 2004; 104:65-72.
40. Semerad CL, Christopher MJ, Liu F, et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005; 106:3020-3027.
41. Zuelzer WW. Myelokathexis: A new form of chronic granulocytopenia. Report of a case. N Engl J Med 1964; 270:699-704.
42. McDermott DH, Liu Q, Ulrick J, et al. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood 2011; 118:4957-4962.
43. Hernandez PA, Gorlin RJ, Lukens JN, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 2003; 34:70-74.
44. Gulino AV, Moratto D, Sozzani S, et al. Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome. Blood 2004; 104:444-452.
45. Kawai T, Choi U, Cardwell L, et al. WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4. Blood 2007; 109:78-84.
46. Balabanian K, Lagane B, Pablos JL, et al. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood 2005; 105:2449-2457.
47. Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999; 10:463-471.
48. Zou YR, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393:595-599.
49. Kawai T, Malech HL. WHIM syndrome: Congenital immune deficiency disease. Curr Opin Hematol 2009; 16:20-26.
50. Nakashima H, Masuda M, Murakami T, et al. Antihuman immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): A possible inhibitor of virus-cell fusion. Antimicrob Agents Chemother 1992; 36:1249-1255.
51. Sison EA, Brown P. The bone marrow microenvironment and leukemia: Biology and therapeutic targeting. Expert Rev Hematol 2011; 4:271-283.
52. De Clercq E, Yamamoto N, Pauwels R, et al. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci U S A 1992; 89:5286-5290.
53. De Clercq E, Yamamoto N, Pauwels R, et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother 1994; 38:668-674.
54. Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44:1667-1673.
55. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102:2728-2730.
56. Flomenberg N, Devine SM, Dipersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106:1867-1874.
57. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colonystimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27:4767-4773.
58. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113:5720-5726.
59. Kuhne MR, Mulvey T, Belanger B, et al. BMS-936564/MDX-1338: A fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res 2013; 19:357-366.
60. Kohem CL, Brezinschek RI, Wisbey H, et al. Enrichment of differentiated CD45RBdim,CD27-memory T cells in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 1996; 39:844-854.
61. Martel-Pelletier J, Welsch DJ, Pelletier JP. Metalloproteases and inhibitors in arthritic diseases. Best Pract Res Clin Rheumatol 2001; 15:805-829.
62. Morimoto C, Romain PL, Fox DA, et al. Abnormalities in CD4 T-lymphocyte subsets in inflammatory rheumatic diseases. Am J Med 1988; 84:817-825.
63. Morita Y, Yamamura M, Kawashima M, et al. Flow cytometric single-cell analysis of cytokine production by CD4 T cells in synovial tissue and peripheral blood from patients with rheumatoid arthritis. Arthritis Rheum 1998; 41:1669-1676.
64. Eck SM, Blackburn JS, Schmucker AC, et al. Matrix metalloproteinase and G protein coupled receptors: Co-conspirators in the pathogenesis of autoimmune disease and cancer. J Autoimmun 2009; 33:214-221.
65. Nanki T, Hayashida K, El-Gabalawy HS, et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4 T cell accumulation in rheumatoid arthritis synovium. J Immunol 2000; 165:6590-6598.
66. De Clercq E. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacol Ther 2010; 128:509-518.
67. Chung SH, Seki K, Choi BI, et al. CXC chemokine receptor 4 expressed in T cells plays an important role in the development of collagen-induced arthritis. Arthritis Res Ther 2010; 12:R188.
68. Matthys P, Hatse S, Vermeire K, et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol 2001; 167:4686-4692.
69. Tamamura H, Fujisawa M, Hiramatsu K, et al. Identification of a CXCR4 antagonist, a T140 analog, as an antirheumatoid arthritis agent. FEBS Lett 2004; 569:99-104.
70. Tamamura H, Fujii N. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Expert Opin Ther Targets 2005; 9:1267-1282.
71. Hummel S, Veltman K, Cichon C, et al. Differential targeting of the E-Cadherin/beta-Catenin complex by gram-positive probiotic lactobacilli improves epithelial barrier function. Appl Environ Microbiol 2012; 78:1140-1147.
72. Mikami S, Nakase H, Yamamoto S, et al. Blockade of CXCL12/CXCR4 axis ameliorates murine experimental colitis. J Pharmacol Exp Ther 2008; 327:383-392.
73. Dotan I, Werner L, Vigodman S, et al. CXCL12 is a constitutive and inflammatory chemokine in the intestinal immune system. Inflamm Bowel Dis 2010; 16:583-592.
74. Xia XM, Wang FY, Zhou J, et al. CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis. PLoS One 2011; 6:e27282.
75. Cencioni C, Capogrossi MC, Napolitano M. The SDF-1/CXCR4 axis in stem cell preconditioning. Cardiovasc Res 2012; 94:400-407.
76. Semenza GL. Surviving ischemia: Adaptive responses mediated by hypoxiainducible factor
77. J Clin Invest 2000; 106:809-812.
78. Williams RS, Benjamin IJ. Protective responses in the ischemic myocardium. J Clin Invest 2000; 106:813-818.
79. Takeshita S, Pu LQ, Stein LA, et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 1994; 90:II228-II234.
80. Takahashi T, Kalka C, Masuda H, et al. Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5:434-438.
81. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473:298-307.
82. Hershey JC, Baskin EP, Glass JD, et al. Revascularization in the rabbit hindlimb: Dissociation between capillary sprouting and arteriogenesis. Cardiovasc Res 2001; 49:618-625.
83. Wen J, Zhang JQ, Huang W, Wang Y. SDF-1alpha and CXCR4 as therapeutic targets in cardiovascular disease. Am J Cardiovasc Dis 2012; 2:20-Here the authors describe in detail the role of the CXCL12/CXCR4 axis and its antagonists in cardiovascular diseases. In particular, they focus on the involvement of CXCR4 in the steps of cell homing/trafficking, and injury/tissue repair.
84. Yamaguchi J, Kusano KF, Masuo O, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003; 107:1322-1328.
85. Zaruba MM, Franz WM. Role of the SDF-1-CXCR4 axis in stem cell-based therapies for ischemic cardiomyopathy. Expert Opin Biol Ther 2010; 10:321-335.
86. Luo Y, Zhao X, Zhou X, et al. Short-term intermittent administration of CXCR4 antagonist AMD3100 facilitates myocardial repair in experimental myocardial infarction. Acta Biochim Biophys Sin (Shanghai) 2013; 45:561-569. This study demonstrated the pivotal role of AMD3100 as CXCR4 antagonist in ischemia/reperfusion injury. Administration of AMD3100 prolongs bone marrow progenitor mobilization and improves the recovery from injury, which illustrates the putative role of AMD3100 as a therapeutic agent in myocardial infarction.
87. Jujo K, Ii M, Sekiguchi H, et al. CXC-chemokine receptor 4 antagonist AMD3100 promotes cardiac functional recovery after ischemia/reperfusion injury via endothelial nitric oxide synthase-dependent mechanism. Circulation 2013; 127:63-73.
88. Toupadakis CA, Wong A, Genetos DC, et al. Long-term administration of AMD3100, an antagonist of SDF-1/CXCR4 signaling, alters fracture repair. J Orthop Res 2012; 30:1853-1859.
89. Maharaj SS, Baroke E, Gauldie J, Kolb MR. Fibrocytes in chronic lung disease: Facts and controversies. Pulm Pharmacol Ther 2012; 25:263-267.
90. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345:517-525.
91. Selman M, King TE, Pardo A, American Thoracic Society; European Respiratory Society; American College of Chest Physicians. Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136-151.
92. American Thoracic Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161:646-664.
93. Abe R, Donnelly SC, Peng T, et al. Peripheral blood fibrocytes: Differentiation pathway and migration to wound sites. J Immunol 2001; 166:7556-7562.
94. Yang L, Scott PG, Giuffre J, et al. Peripheral blood fibrocytes from burn patients: Identification and quantification of fibrocytes in adherent cells cultured from peripheral blood mononuclear cells. Lab Invest 2002; 82:1183-1192.
95. Hashimoto N, Jin H, Liu T, et al. Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 2004; 113:243-252.
96. Phillips RJ, Burdick MD, Hong K, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004; 114:438-446.
97. Andersson-Sjoland A, de Alba CG, Nihlberg K, et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008; 40:2129-2140.
98. Mehrad B, Burdick MD, Zisman DA, et al. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007; 353:104-108.
99. Song JS, Kang CM, Kang HH, et al. Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis. Exp Mol Med 2010; 42:465-472.
100. Makino H, Aono Y, Azuma M, et al. Antifibrotic effects of CXCR4 antagonist in bleomycin-induced pulmonary fibrosis in mice. J Med Invest 2013; 60:127-137.